SCHEDULE 13G: Mike Newlin Discloses 5.58% Stake in FibroBiologics, Inc. via Schedule 13G Filing
Beneficial Ownership Disclosure
Mike Newlin has filed a Schedule 13G, disclosing beneficial ownership of 2,134,853 shares, representing 5.579% of FibroBiologics, Inc.'s common stock.
Summary
- Mike Newlin has filed a Schedule 13G with the SEC, indicating beneficial ownership of FibroBiologics, Inc. common stock.
- The filing reports that Mike Newlin beneficially owns 2,134,853 shares of FibroBiologics, Inc. common stock.
- This ownership represents 5.579% of the Issuer's common stock outstanding.
- The beneficial ownership percentage is based on 38,262,586 shares of common stock outstanding as of May 13, 2025, as disclosed in FibroBiologics, Inc.'s Quarterly Report on Form 10-Q filed on May 14, 2025.
- The shares are held in the name of Golden Knight Incorporated, L.P., of which Mike Newlin is the 100% beneficial owner.
- The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the sentiment towards the company's operational or financial performance.
Positives
- A significant stake by an individual investor like Mike Newlin can be perceived as a vote of confidence in FibroBiologics, Inc.'s long-term prospects.
Risks
- The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating potential governance risks associated with activist investors.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding FibroBiologics, Inc.'s future outlook.
Industry Context
This filing is a standard disclosure of a significant ownership stake by an individual investor and does not provide specific insights into broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant individual investor's stake in the company, which can influence investor perception and potentially trading activity.
Key Dates
| Date | Description |
|---|---|
| 08/09/2024 | Date of event which required the filing of this statement |
| 05/13/2025 | Date as of which 38,262,586 shares of common stock were issued and outstanding, as disclosed in the Issuer's Form 10-Q |
| 05/14/2025 | Date FibroBiologics, Inc. filed its Quarterly Report on Form 10-Q with the SEC |
| 06/05/2025 | Date of filing/signature of the Schedule 13G statement |
Keywords
FibroBiologics, Mike Newlin, Schedule 13G, beneficial ownership, common stock, SEC filing, investor, equity stake, Golden Knight Incorporated
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.